Determining Clinical Profile of Parkinson's Disease Among Egyptian Population
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Parkinson's Disease
- Sponsor
- Zagazig University
- Enrollment
- 500
- Locations
- 1
- Primary Endpoint
- Non-motor symptoms
- Last Updated
- 8 years ago
Overview
Brief Summary
Parkinson's disease is the second most common neurodegenerative disease affecting about 1-3% of population above 60 years. Recently, non-motor symptoms are getting more attention in PD management. The pattern of PD onset and clinical course differ from one population to another. Many studies have been conducted to determine the clinical profile of PD in populations worldwide. However, no similar studies have been conducted in Egypt. Therefore, the investigators will conduct a nation-wide, collaborative, cross sectional study to determine the pattern of Parkinson's disease onset, clinical course, and non-motor symptoms among Egyptian population.
Investigators
Ahmed Negida
(1) Principal Investigator; (2) Head of Scientific Committee, Student Research Unit, Zagazig University; and (3) Head of Scientific Committee, Egyptian National Research Collaborative.
Zagazig University
Eligibility Criteria
Inclusion Criteria
- •Patients who meet the Parkinson's disease criteria of United Kingdom Brain Bank within the study centres.
Exclusion Criteria
- •Patients with vascular Parkinsonism (history of stroke)
- •Patients with treatment induced Parkinsonism
- •Patients with history of dopaminergic neurotoxin (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine)
Outcomes
Primary Outcomes
Non-motor symptoms
Time Frame: At enrolment
Non-motor symptoms measured by the non-motor symptoms questionnaire (NMS)
Side of initial motor symptoms
Time Frame: At enrolment
Number of patients with either right or left side initial motor symptoms.
Levodopa equivalent dose
Time Frame: At enrolment
Current dose of levodopa per day
Time to diagnosis
Time Frame: At enrolment
Duration, in years, from appearance of initial symptom to receiving Parkinson's disease diagnosis.
Initial motor symptom
Time Frame: At enrolment
Number of patients with each initial motor symptom (tremor, rigidity, or bradykinesia).
Quality of life
Time Frame: At enrolment
Mobility, activities of daily living, emotional well-being, stigma, social support, cognition, communication, and bodily discomfort assessed by the parkinson's disease quality of life questionnaire (PDQ-39).
Age at disease onset
Time Frame: At enrolment
Patients age when the initial symptom appeared.
Clinical subtype of the disease
Time Frame: At enrolment
Number patients with each disease subtype (tremor dominant Parkinson's disease, hypokinetic-rigid dominant Parkinson's disease, or postural instability and gait disturbance dominant Parkinson's disease).
Duration of levodopa treatment from disease onset
Time Frame: At enrolment
Number of years on levodopa treatment since receiving parkinson's disease diagnosis
Secondary Outcomes
- Stage of the disease [optional](At enrolment)
- Motor Functions [optional](At enrolment)